ALX Oncology Holdings Inc. (ALXO) — Financial statements
Income statement, balance sheet, and cash flow for ALX Oncology Holdings Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 77↓33.8% | 116↓17.9% | 142↑44.1% | 98↑63.5% | 60 | |
| General & Administrative Expenses | 24↓8.6% | 26↓8.4% | 28↓1.9% | 29↑24.2% | 23 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 24↓8.6% | 26↓8.4% | 28↓1.9% | 29↑24.2% | 23 | |
| Other Expenses | 3 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 104↓27.0% | 142↓16.3% | 170↑33.6% | 127↑52.5% | 84 | |
| Total Costs & Expenses | 104↓27.0% | 142↓16.3% | 170↑33.6% | 127↑52.5% | 84 | |
| Operating Results | ||||||
| Operating Income | -104↑27.0% | -142↑16.3% | -170↓33.6% | -127↓52.5% | -84 | |
| Depreciation & Amortization | 0.71↓19.0% | 0.87↑4.3% | 0.84↑144.4% | 0.34↑570.6% | 0.05 | |
| EBITDA | -99↑24.8% | -132↑16.5% | -158↓29.0% | -123↓47.3% | -83 | |
| EBIT | -100↑24.8% | -133↑16.4% | -159↓29.3% | -123↓47.6% | -83 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↓69.1% | 8↓15.9% | 9↑124.9% | 4↑31396.0% | -0.01 | |
| Interest Income | 4↓57.7% | 9↓12.0% | 11↑148.9% | 4↑4700998.9% | 0.00 | |
| Interest Expense | 2↓7.3% | 2↑10.5% | 2↑557.6% | 0.24↑1730.8% | 0.01 | |
| Non-Operating Income | -4↑58.0% | -9↑15.3% | -11↓159.4% | -4↓4966.7% | -0.08 | |
| Other Income / Expenses | 2↓69.5% | 8↓19.6% | 9↑135.8% | 4↑5559.2% | 0.07 | |
| Income Before Tax | -102↑24.6% | -135↑16.1% | -161↓30.3% | -123↓47.8% | -83 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.06↑404.8% | -0.02 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -102↑24.6% | -135↑16.1% | -161↓30.2% | -123↓47.9% | -83 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -102↑24.6% | -135↑16.1% | -161↓30.2% | -123↓47.9% | -83 | |
| Bottom-Line Net Income | -102↑24.6% | -135↑16.1% | -161↓30.2% | -123↓47.9% | -83 | |
| EPS (Basic) | -1.90↑26.4% | -2.58↑31.0% | -3.74↓23.4% | -3.03↓46.4% | -2.07 | |
| EPS (Diluted) | -1.90↑26.4% | -2.58↑31.0% | -3.74↓23.4% | -3.03↓46.4% | -2.07 | |
| Weighted Average Shares | 54↑2.8% | 52↑21.4% | 43↑5.6% | 41↑1.0% | 40 | |
| Weighted Average Diluted Shares | 54↑2.8% | 52↑21.4% | 43↑5.6% | 41↑1.0% | 40 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.